5.4.3 HyperHEP B | New Zealand Blood Service
Transfusion medicine

Transfusion medicine handbook

The Transfusion Medicine Handbook is designed to assist hospital staff and other health professionals in modern Transfusion Medicine Practice.

5. Fractionated Products

5.4.3 HyperHEP B

HyperHEP B is a sterile, preservative-free, solvent/detergent-treated solution containing not less than 220 IU/mL neutralising hepatitis B antibodies. Donations used in the preparation of HyperHEP B are selected on the basis that they contain high levels of specific antibodies against HBsAg. HyperHEP B is supplied as a 0.5 mL neonatal single-dose syringe containing at least 110 IU of hepatitis B immunoglobulin, intended for intramuscular injection[6].

Indications for Use

HyperHEP B is indicated for:

  • Infants born to HBsAg-positive mothers, either chronic carriers or those who contract hepatitis B during pregnancy

Dosage and Administration

The infant should receive a single 110 IU neonatal dose of HyperHEP B at birth. The dose is preferably given within 12 hours of birth as efficacy decreases markedly if treatment is delayed beyond 48 hours. Hepatitis B vaccine should be administered concurrently with hepatitis B immunoglobulin (or at most within 7 days) but at a separate site. If administration of the first dose of hepatitis B vaccine is delayed for as long as 3 months, then a 0.5 mL dose of HyperHEP B should be repeated at 3 months. If vaccine is refused, the 0.5 mL dose of HyperHEP B should be repeated at 3 and 6 months.

Unsupported Browser!
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.